ZA200408596B - Demsmopressin in an orodispersible dosage form - Google Patents

Demsmopressin in an orodispersible dosage form Download PDF

Info

Publication number: ZA200408596B
Authority: ZA; South Africa
Prior art keywords: dosage form; desmopressin; composition; pharmaceutical dosage; orodispersible
Prior art date: 2002-05-07

Application number

ZA200408596A

Other languages

English (en)

Inventor

Lars A R Nilsson

Hans Lidner

Jensen J Wittendorff

Original Assignee

Ferring Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-07

Filing date

2004-10-22

Publication date

2006-06-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9936186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200408596(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-10-22 Application filed by Ferring Bv filed Critical Ferring Bv

2006-06-28 Publication of ZA200408596B publication Critical patent/ZA200408596B/en

Links

239000002552 dosage form Substances 0.000 title claims description 64
239000000203 mixture Substances 0.000 claims description 38
108010000437 Deamino Arginine Vasopressin Proteins 0.000 claims description 33
229960004281 desmopressin Drugs 0.000 claims description 33
238000000034 method Methods 0.000 claims description 23
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
239000007787 solid Substances 0.000 claims description 17
239000011159 matrix material Substances 0.000 claims description 15
208000008967 Enuresis Diseases 0.000 claims description 11
108010010803 Gelatin Proteins 0.000 claims description 10
239000008273 gelatin Substances 0.000 claims description 10
229920000159 gelatin Polymers 0.000 claims description 10
235000019322 gelatine Nutrition 0.000 claims description 10
235000011852 gelatine desserts Nutrition 0.000 claims description 10
108090000765 processed proteins & peptides Proteins 0.000 claims description 10
239000000126 substance Substances 0.000 claims description 8
239000003814 drug Substances 0.000 claims description 7
238000011282 treatment Methods 0.000 claims description 7
208000003450 Neurogenic Diabetes Insipidus Diseases 0.000 claims description 6
208000028235 central diabetes insipidus Diseases 0.000 claims description 6
201000010064 diabetes insipidus Diseases 0.000 claims description 6
201000005119 neurohypophyseal diabetes insipidus Diseases 0.000 claims description 6
206010029446 nocturia Diseases 0.000 claims description 6
206010021639 Incontinence Diseases 0.000 claims description 5
201000010099 disease Diseases 0.000 claims description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical class C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims description 2
NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 claims 17
239000002904 solvent Substances 0.000 claims 7
239000012876 carrier material Substances 0.000 claims 6
238000004519 manufacturing process Methods 0.000 claims 5
241000251468 Actinopterygii Species 0.000 claims 4
230000002265 prevention Effects 0.000 claims 4
238000004108 freeze drying Methods 0.000 claims 2
231100000252 nontoxic Toxicity 0.000 claims 2
230000003000 nontoxic effect Effects 0.000 claims 2
238000000859 sublimation Methods 0.000 claims 2
230000008022 sublimation Effects 0.000 claims 2
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 claims 1
URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 claims 1
102000005157 Somatostatin Human genes 0.000 claims 1
108010056088 Somatostatin Proteins 0.000 claims 1
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims 1
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 claims 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical group C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 1
229960000553 somatostatin Drugs 0.000 claims 1
238000002560 therapeutic procedure Methods 0.000 claims 1
239000003826 tablet Substances 0.000 description 22
238000009472 formulation Methods 0.000 description 21
239000003795 chemical substances by application Substances 0.000 description 20
NFLWUMRGJYTJIN-PNIOQBSNSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-PNIOQBSNSA-N 0.000 description 17
210000000214 mouth Anatomy 0.000 description 17
239000004480 active ingredient Substances 0.000 description 13
238000007907 direct compression Methods 0.000 description 12
235000000346 sugar Nutrition 0.000 description 12
229920001817 Agar Polymers 0.000 description 10
239000008272 agar Substances 0.000 description 10
239000007884 disintegrant Substances 0.000 description 10
239000000463 material Substances 0.000 description 10
239000000945 filler Substances 0.000 description 9
239000002245 particle Substances 0.000 description 8
238000004090 dissolution Methods 0.000 description 6
239000000314 lubricant Substances 0.000 description 6
210000004877 mucosa Anatomy 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
239000007789 gas Substances 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
230000001681 protective effect Effects 0.000 description 4
210000003296 saliva Anatomy 0.000 description 4
239000000243 solution Substances 0.000 description 4
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000002411 adverse Effects 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
230000035807 sensation Effects 0.000 description 3
239000006190 sub-lingual tablet Substances 0.000 description 3
150000008163 sugars Chemical class 0.000 description 3
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
159000000021 acetate salts Chemical class 0.000 description 2
238000013019 agitation Methods 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000012458 free base Substances 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000011859 microparticle Substances 0.000 description 2
239000007922 nasal spray Substances 0.000 description 2
229940097496 nasal spray Drugs 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
230000035515 penetration Effects 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
229940098466 sublingual tablet Drugs 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
150000005846 sugar alcohols Chemical class 0.000 description 2
230000032258 transport Effects 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
239000004925 Acrylic resin Substances 0.000 description 1
229920000178 Acrylic resin Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
229920003134 Eudragit® polymer Polymers 0.000 description 1
DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
244000299461 Theobroma cacao Species 0.000 description 1
235000009470 Theobroma cacao Nutrition 0.000 description 1
241000700605 Viruses Species 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229940069428 antacid Drugs 0.000 description 1
239000003159 antacid agent Substances 0.000 description 1
230000002686 anti-diuretic effect Effects 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
210000004081 cilia Anatomy 0.000 description 1
238000005056 compaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000007983 food acid Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000011521 glass Substances 0.000 description 1
229940049654 glyceryl behenate Drugs 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
229920000591 gum Polymers 0.000 description 1
229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
238000007654 immersion Methods 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000014380 magnesium carbonate Nutrition 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
210000002200 mouth mucosa Anatomy 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000007935 oral tablet Substances 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000003961 penetration enhancing agent Substances 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
239000011736 potassium bicarbonate Substances 0.000 description 1
229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
235000015497 potassium bicarbonate Nutrition 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
235000011181 potassium carbonates Nutrition 0.000 description 1
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
-1 preferably Chemical class 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
239000000376 reactant Substances 0.000 description 1
235000020071 rectified spirit Nutrition 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000028327 secretion Effects 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000017550 sodium carbonate Nutrition 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
239000008279 sol Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
239000001993 wax Substances 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Zoology (AREA)
Inorganic Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Obesity (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ZA200408596A 2002-05-07 2004-10-22 Demsmopressin in an orodispersible dosage form ZA200408596B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0210397.6A GB0210397D0 (en)	2002-05-07	2002-05-07	Pharmaceutical formulations

Publications (1)

Publication Number	Publication Date
ZA200408596B true ZA200408596B (en)	2006-06-28

Family

ID=9936186

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200408596A ZA200408596B (en)	2002-05-07	2004-10-22	Demsmopressin in an orodispersible dosage form

Country Status (22)

Country	Link
US (14)	US7560429B2 (es)
EP (1)	EP1501534B1 (es)
KR (1)	KR100632455B1 (es)
CN (2)	CN1981745A (es)
AR (3)	AR039092A1 (es)
AT (1)	ATE333886T1 (es)
AU (2)	AU2002337419A1 (es)
DK (1)	DK1501534T5 (es)
ES (1)	ES2266820T4 (es)
GB (1)	GB0210397D0 (es)
HK (1)	HK1074393A1 (es)
IL (1)	IL164519A (es)
MX (1)	MXPA04010926A (es)
MY (1)	MY131153A (es)
PL (1)	PL208482B1 (es)
RU (1)	RU2292903C2 (es)
SI (1)	SI1501534T1 (es)
TW (1)	TWI315202B (es)
UA (1)	UA85664C2 (es)
UY (2)	UY27683A1 (es)
WO (2)	WO2003094885A1 (es)
ZA (1)	ZA200408596B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT409081B (de) *	2000-02-16	2002-05-27	Gebro Pharma Gmbh	Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
US20040236673A1 (en) *	2000-10-17	2004-11-25	Eder Jeff Scott	Collaborative risk transfer system
US20080027769A1 (en)	2002-09-09	2008-01-31	Jeff Scott Eder	Knowledge based performance management system
US20080256069A1 (en) *	2002-09-09	2008-10-16	Jeffrey Scott Eder	Complete Context(tm) Query System
US20110040631A1 (en) *	2005-07-09	2011-02-17	Jeffrey Scott Eder	Personalized commerce system
GB0210397D0 (en)	2002-05-07	2002-06-12	Ferring Bv	Pharmaceutical formulations
CA2545194C (en) *	2003-11-10	2014-10-21	Seymour H. Fein	Pharmaceutical compositions including low dosages of desmopressin
DK1530967T3 (da)	2003-11-13	2006-07-03	Ferring Bv	Blisterpakning og dertil hörende fast dosisform
GB0406048D0 (en) *	2004-03-18	2004-04-21	Ardana Bioscience Ltd	Drug formulations
US20090043637A1 (en) *	2004-06-01	2009-02-12	Eder Jeffrey Scott	Extended value and risk management system
US7972621B2 (en)	2004-06-03	2011-07-05	R.P. Scherer Technologies, Llc	Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight
US8713025B2 (en)	2005-03-31	2014-04-29	Square Halt Solutions, Limited Liability Company	Complete context search system
SE528446C2 (sv) *	2006-03-02	2006-11-14	Ferring Int Ct Sa	Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
US8498915B2 (en)	2006-04-02	2013-07-30	Asset Reliance, Inc.	Data processing framework for financial services
US7788434B2 (en) *	2006-12-15	2010-08-31	Microchip Technology Incorporated	Interrupt controller handling interrupts with and without coalescing
EP1967202A1 (en) *	2007-03-05	2008-09-10	AEterna Zentaris GmbH	Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
KR20140143461A (ko) *	2007-08-06	2014-12-16	알레간 인코포레이티드	데스모프레신 약물 전달을 위한 방법 및 장치
ES2319054B1 (es)	2007-08-06	2010-02-12	Gp Pharm S.A.	Composicion farmaceutica oral de desmopresina.
CN101372504B (zh) *	2007-08-22	2011-05-18	深圳翰宇药业股份有限公司	一种纯化去氨加压素的方法
US20100121307A1 (en) *	2007-08-24	2010-05-13	Microfabrica Inc.	Microneedles, Microneedle Arrays, Methods for Making, and Transdermal and/or Intradermal Applications
DK2712622T3 (en)	2008-05-21	2016-09-12	Ferring Bv	Orodispergibel desmopressin to the extension of the initial period of sleep, undisturbed by nocturia.
US11963995B2 (en)	2008-05-21	2024-04-23	Ferring B.V.	Methods comprising desmopressin
US20100286045A1 (en)	2008-05-21	2010-11-11	Bjarke Mirner Klein	Methods comprising desmopressin
JP5731396B2 (ja)	2008-12-22	2015-06-10	アラガン，インコーポレイティド	鼻腔内デスモプレシン投与
US20100160214A1 (en) *	2008-12-22	2010-06-24	Serenity Pharmaceuticals Corporation	Desmopressin composition
AU2015261630B2 (en) *	2008-12-22	2017-09-14	Acerus Pharmaceuticals USA, LLC	Intranasal desmopressin administration
DK2442821T3 (en) *	2009-06-18	2017-10-02	Allergan Inc	SECURE ADMINISTRATION OF DESMOPRESSIN
NO2493457T3 (es)	2009-10-30	2018-01-06
US12186426B2 (en)	2009-10-30	2025-01-07	Ix Biopharma Ltd.	Solid dosage form
GB0920041D0 (en) *	2009-11-16	2009-12-30	Univ Aston	Tablet
CN102834091B (zh) *	2010-03-29	2015-04-22	辉凌公司	一种快速溶解药物组合物
JO3112B1 (ar)	2010-03-29	2017-09-20	Ferring Bv	تركيبة دوائية سريعة التحلل
PT3095441T (pt) *	2010-10-08	2021-01-14	Scherer Technologies Llc R P	Forma de dosagem de dissolução rápida de vacina oral utilizando amido
NZ620897A (en)	2011-09-16	2016-07-29	Ferring Bv	A fast dissolving pharmaceutical composition
EP2872177B1 (en) *	2012-07-12	2017-12-20	Ferring BV	Diclofenac formulations
TW201422254A (zh)	2012-11-21	2014-06-16	Ferring Bv	用於速釋及延釋的組成物
US20150306170A1 (en) *	2012-11-21	2015-10-29	Ferring B.V.	Composition for immediate and extended release
US11554229B2 (en)	2013-03-26	2023-01-17	OptiNose Inc.	Nasal administration
CN105263551A (zh) *	2013-03-26	2016-01-20	奥普蒂诺斯公司	鼻腔给药
AU2014293141A1 (en)	2013-07-23	2016-02-18	Serenity Pharmaceuticals Llc	Methods and compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist
CN105579056A (zh) *	2013-07-23	2016-05-11	阿勒根公司	包含与5-α还原酶抑制剂组合的去氨加压素的方法和组合物
WO2015063602A1 (en)	2013-10-29	2015-05-07	Ferring B.V.	Desmopressin and blood glucose
KR20150144209A (ko) *	2014-06-16	2015-12-24	훼링 비.브이.	안정화된 데스모프레신 또는 이의 약학적으로 허용가능한 염을 함유 약학 조성물
US10286033B2 (en)	2014-11-20	2019-05-14	Serenity Pharmaceuticals, Llc	Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist
ITUB20156821A1 (it) *	2015-12-09	2017-06-09	Altergon Sa	CAPSULE DI GELATINA MOLLE A RILASCIO pH INDIPENDENTE
RU2751193C2 (ru)	2017-01-11	2021-07-12	Ферринг Б.В.	Быстро распадающаяся фармацевтическая композиция
CN108113974A (zh) *	2018-02-05	2018-06-05	上海祺宇生物科技有限公司	一种多孔性空心胶囊的制备方法以及由此制备的胶囊
US10940088B1 (en)	2020-01-09	2021-03-09	King Saud University	Method of preparing low dose pharmaceutical formulations
US11672761B2 (en)	2020-11-16	2023-06-13	Orcosa Inc.	Rapidly infusing platform and compositions for therapeutic treatment in humans
CA3229017A1 (en) *	2021-08-19	2023-02-23	Mind Medicine, Inc.	Lyophilized orally disintegrating tablet formulations of d-lysergic acid diethylamide for therapeutic applications
US12214010B2 (en)	2023-04-04	2025-02-04	Tulex Pharmaceuticals Inc.	Desmopressin oral compositions

Family Cites Families (181)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3989816A (en)	1975-06-19	1976-11-02	Nelson Research & Development Company	Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4316893A (en)	1975-06-19	1982-02-23	Nelson Research & Development Co.	Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4405616A (en)	1975-06-19	1983-09-20	Nelson Research & Development Company	Penetration enhancers for transdermal drug delivery of systemic agents
GB1548022A (en)	1976-10-06	1979-07-04	Wyeth John & Brother Ltd	Pharmaceutial dosage forms
US4285858A (en)	1979-10-30	1981-08-25	Mt. Sinai School Of Medicine Of The City University Of N.Y.	Vasopressin analogs
US4337242A (en) *	1980-02-05	1982-06-29	Merck & Co., Inc.	Vaccine stabilizer containing L-glutamic acid and L-arginine
US4263283A (en) *	1980-05-16	1981-04-21	Ferring Pharmaceuticals, Inc.	Method for prophylaxis and/or treatment of sickle cell disease
US4371316A (en) *	1981-03-23	1983-02-01	Michael Ivic	Control for a bilge pump
GB2111423B (en)	1981-12-02	1985-06-26	Wyeth John & Brother Ltd	Making quick-dissolving pills
EP0084705B1 (en)	1981-12-11	1987-01-14	JOHN WYETH & BROTHER LIMITED	Process for preparing solid shaped articles
CA1208558A (en) *	1982-10-07	1986-07-29	Kazuo Kigasawa	Soft buccal
US4557934A (en)	1983-06-21	1985-12-10	The Procter & Gamble Company	Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
SE8306367L (sv)	1983-11-18	1985-05-19	Ferring Ab	Antidiuretiskt verkande farmaceutiskt preparat
US4863737A (en)	1985-05-01	1989-09-05	University Of Utah	Compositions and methods of manufacture of compressed powder medicaments
US4623283A (en) *	1984-06-13	1986-11-18	Mobil Oil Corporation	Method for controlling water influx into underground cavities
US4588580B2 (en)	1984-07-23	1999-02-16	Alaz Corp	Transdermal administration of fentanyl and device therefor
US5288497A (en) *	1985-05-01	1994-02-22	The University Of Utah	Compositions of oral dissolvable medicaments
US4731360A (en)	1985-08-16	1988-03-15	Merck & Co., Inc.	Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
US4764378A (en)	1986-02-10	1988-08-16	Zetachron, Inc.	Buccal drug dosage form
IE60941B1 (en)	1986-07-10	1994-09-07	Elan Transdermal Ltd	Transdermal drug delivery device
US4878892A (en)	1987-02-10	1989-11-07	Drug Delivery Systems Inc.	Electrolytic transdermal delivery of polypeptides
US4783450A (en)	1987-04-13	1988-11-08	Warner-Lambert Company	Use of commercial lecithin as skin penetration enhancer
US4878592A (en) *	1988-06-28	1989-11-07	Zarn, Inc.	Apparatus for segregated refuse collection
US5350741A (en) *	1988-07-30	1994-09-27	Kanji Takada	Enteric formulations of physiologically active peptides and proteins
EP0381345B1 (en) *	1989-01-30	1994-07-13	Corint, Ltd.	Aqueous liquid desmopressin-CMC pharmaceutical composition
US5091186A (en)	1989-08-15	1992-02-25	Cygnus Therapeutic Systems	Biphasic transdermal drug delivery device
TW279133B (es)	1990-12-13	1996-06-21	Elan Med Tech
US5527288A (en)	1990-12-13	1996-06-18	Elan Medical Technologies Limited	Intradermal drug delivery device and method for intradermal delivery of drugs
SE9101022D0 (sv)	1991-01-09	1991-04-08	Paal Svedman	Medicinsk suganordning
US6746678B1 (en)	1991-02-22	2004-06-08	Howard K. Shapiro	Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
CA2070061C (en)	1991-06-07	2004-02-10	Shigeyuki Takama	Physiologically active polypeptide-containing pharmaceutical composition
US5464387A (en)	1991-07-24	1995-11-07	Alza Corporation	Transdermal delivery device
AU666509B2 (en)	1991-12-24	1996-02-15	Yamanouchi Pharmaceutical Co., Ltd.	Intrabuccally disintegrating preparation and production thereof
US5298256A (en) *	1992-04-28	1994-03-29	Corint, Ltd.	Desmopressin buccal patch composition
US5534496A (en)	1992-07-07	1996-07-09	University Of Southern California	Methods and compositions to enhance epithelial drug transport
DE4226753A1 (de) *	1992-08-13	1994-02-17	Basf Ag	Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen
US5343672A (en)	1992-12-01	1994-09-06	Scherer Ltd R P	Method for manufacturing freeze dried dosages in a multilaminate blister pack
CA2090738C (en) *	1993-02-24	1996-05-21	Hema-Quebec	Use of paf
SE9300937L (sv)	1993-03-19	1994-09-20	Anne Fjellestad Paulsen	Komposition för oral administrering av peptider
SE501677C2 (sv)	1993-06-18	1995-04-10	Ferring Bv	Biologiskt aktiva vasopressinanaloger, farmaceutiska preparat innehållande dem samt deras användning för framställning av läkemedel
ATE193892T1 (de)	1993-06-29	2000-06-15	Ferring Bv	Synthese zyklischer peptide
NZ268442A (en)	1993-06-29	1996-09-25	Ferring Bv	Aqueous composition of desmopressin for nasal spray administration
US5985835A (en) *	1993-12-23	1999-11-16	Ferring B.V.	Desmopressin for nocturia, incontinence and enuresis
US5500413A (en)	1993-06-29	1996-03-19	Ferring Ab	Process for manufacture of 1-deamino-8-D-arginine vasopressin
US5674850A (en)	1993-12-23	1997-10-07	Ferring Ab	High purity desmopressin produced in large single batches
US5482931A (en)	1993-06-29	1996-01-09	Ferring Ab	Stabilized pharmaceutical peptide compositions
US5514670A (en) *	1993-08-13	1996-05-07	Pharmos Corporation	Submicron emulsions for delivery of peptides
DE69434626D1 (de) *	1993-11-17	2006-04-20	Athena Neurosciences Inc	Transparente flüssigkeit zur verabreichung von verkapselten medikamenten
WO1995018602A1 (en) *	1994-01-11	1995-07-13	Alkermes Controlled Therapeutics, Inc.	ORAL DOSAGE FORM OF DESMOPRESSIN (dDAVP)
US5595761A (en) *	1994-01-27	1997-01-21	The Board Of Regents Of The University Of Oklahoma	Particulate support matrix for making a rapidly dissolving tablet
US5576014A (en) *	1994-01-31	1996-11-19	Yamanouchi Pharmaceutical Co., Ltd	Intrabuccally dissolving compressed moldings and production process thereof
SE9400918L (sv)	1994-03-18	1995-09-19	Anne Fjellstad Paulsen	Stabiliserad komposition för oral administrering av peptider
KR0134152B1 (ko)	1994-05-23	1998-04-14	이형도	의약품 투여용 피부흠집 형성장치
US5611806A (en)	1994-05-23	1997-03-18	Samsung Electro-Mechanics Co., Ltd.	Skin perforating device for transdermal medication
GB9410388D0 (en)	1994-05-24	1994-07-13	Erba Carlo Spa	Method for the preparation of 9-amino camptothecin
US5495898A (en) *	1994-07-13	1996-03-05	Champion Road Machinery Limited	Blade control system for motor graders
SE518619C2 (sv)	1994-12-09	2002-10-29	Gs Dev Ab	Komposition för reglerad frisättning innehållande monokaproin
GB9502879D0 (en)	1995-02-14	1995-04-05	Oxford Biosciences Ltd	Particle delivery
IL113459A (en)	1995-04-23	2000-07-16	Electromagnetic Bracing System	Electrophoretic cuff apparatus
AU5740496A (en)	1995-05-22	1996-12-11	General Hospital Corporation, The	Micromechanical device and method for enhancing delivery of compounds through the skin
GB9516268D0 (en) *	1995-08-08	1995-10-11	Danbiosyst Uk	Compositiion for enhanced uptake of polar drugs from the colon
US5849322A (en)	1995-10-23	1998-12-15	Theratech, Inc.	Compositions and methods for buccal delivery of pharmaceutical agents
DE19602757A1 (de)	1996-01-26	1997-07-31	Boehringer Mannheim Gmbh	Feste Instant-Release-Darreichungsformen und Verfahren zu ihrer Herstellung
US5843016A (en)	1996-03-18	1998-12-01	Physion S.R.L.	Electromotive drug administration for treatment of acute urinary outflow obstruction
TW411277B (en)	1996-05-13	2000-11-11	Hisamitsu Pharmaceutical Co	Percutaneous tape preparation containing fentanyl
DK0914178T3 (da) *	1996-06-18	2003-04-22	Alza Corp	Anordning til forøgelse af transdermal afgivelse eller prøveudtagning af et middel
US5763398A (en)	1996-06-20	1998-06-09	Ferring B.V.	Nasal administration of desmopressin
US5922680A (en)	1996-10-23	1999-07-13	Ferring, B.V.	Stabilized composition for oral administration of peptides
SE9604341D0 (sv)	1996-11-26	1996-11-26	Ferring Bv	Hepta-peptide oxytocin analogue
US5968895A (en) *	1996-12-11	1999-10-19	Praecis Pharmaceuticals, Inc.	Pharmaceutical formulations for sustained drug delivery
FR2758195B1 (fr)	1997-01-09	1999-02-26	Sgs Thomson Microelectronics	Coprocesseur d'arithmetique modulaire comprenant deux circuits de multiplication operant en parallele
US5985385A (en)	1997-05-23	1999-11-16	No Fire Technologies, Inc.	Fire and heat protection wrap for conduits, cable trays, other electrical transmission lines and gas and oil pipelines
US6194407B1 (en)	1997-07-30	2001-02-27	American Home Products Corporation	Tricyclic pyrido vasopressin agonists
US5932745A (en)	1997-07-30	1999-08-03	American Home Products Corporation	Process for converting propargylic amine-N-oxides to enaminones
US6511974B1 (en)	1997-07-30	2003-01-28	Wyeth	Tricyclic vasopressin agonists
US5948433A (en)	1997-08-21	1999-09-07	Bertek, Inc.	Transdermal patch
US7153845B2 (en)	1998-08-25	2006-12-26	Columbia Laboratories, Inc.	Bioadhesive progressive hydration tablets
US6248358B1 (en) *	1998-08-25	2001-06-19	Columbia Laboratories, Inc.	Bioadhesive progressive hydration tablets and methods of making and using the same
US20040018241A1 (en)	1997-09-26	2004-01-29	Noven Pharmaceuticals, Inc.	Bioadhesive compositions and methods for topical administration of active agents
US5843477A (en) *	1997-09-30	1998-12-01	Bayer Corporation	Lubricants for use in tabletting
US6248636B1 (en) *	1998-05-28	2001-06-19	Samsung Electronics Co., Ltd.	Method for forming contact holes of semiconductor memory device
US6322532B1 (en)	1998-06-24	2001-11-27	3M Innovative Properties Company	Sonophoresis method and apparatus
US6090803A (en)	1998-07-24	2000-07-18	American Home Products Corporation	Tricyclic vasopressin agonists
US7138393B2 (en)	1998-07-24	2006-11-21	Wyeth	Biologically active vasopressin agonist metabolites
US6423346B1 (en) *	1998-08-25	2002-07-23	Basf Health & Nutrition A/S	Fish gelatinous composition for use as an ingredient in tablets
US6148232A (en)	1998-11-09	2000-11-14	Elecsys Ltd.	Transdermal drug delivery and analyte extraction
GB9827292D0 (en)	1998-12-12	1999-02-03	Univ Strathclyde	Freeze drying
US6406455B1 (en)	1998-12-18	2002-06-18	Biovalve Technologies, Inc.	Injection devices
US20060025387A1 (en)	1998-12-23	2006-02-02	Cytoscan Sciences Llc	Compositions and methods for the treatment of disorders of the central and peripheral nervous systems
US6355270B1 (en) *	1999-01-11	2002-03-12	The Regents Of The University Of California	Particles for oral delivery of peptides and proteins
GB9901819D0 (en)	1999-01-27	1999-03-17	Scherer Corp R P	Pharmaceutical compositions
US6620807B1 (en)	1999-02-04	2003-09-16	Wyeth	Pyridobenzodiazepine and pyridobenzoxazepine carboxyamide vasopressin agonists
US6235900B1 (en)	1999-02-04	2001-05-22	American Home Products Corporation	Tricyclic pyridine N-oxides vasopressin agonists
US6344451B1 (en)	1999-02-04	2002-02-05	American Home Products	Pyrrolobenzodiazepine carboxyamide vasopressin agonists
US6297234B1 (en)	1999-02-04	2001-10-02	American Home Products Corporation	Arylthiophene vasopressin agonists
EP1153616B1 (en) *	1999-02-15	2004-12-01	Sumitomo Pharmaceuticals Company, Limited	Tablets quickly disintegrated in the oral cavity
WO2000048669A1 (en)	1999-02-18	2000-08-24	Biovalve Technologies, Inc.	Electroactive pore
AR014640A1 (es) *	1999-02-23	2001-03-28	Univ Nac Quilmes	UNA COMPOSICíoN FARMACÉUTICA INHIBIDORA DE LA DISEMINACIoN METASTÁSICA DURANTE LA CIRUGíA DE UN TUMOR CANCEROSO, UN PROCEDIMENTO DE PREPARACIoN Y UN KIT PARA UNA FORMULACIoN INYECTABLE.
US6248363B1 (en)	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7060708B2 (en)	1999-03-10	2006-06-13	New River Pharmaceuticals Inc.	Active agent delivery systems and methods for protecting and administering active agents
US6210699B1 (en)	1999-04-01	2001-04-03	Watson Pharmaceuticals, Inc.	Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
GB9908014D0 (en) *	1999-04-08	1999-06-02	Scherer Corp R P	Pharmaceutical compositions
US6720001B2 (en)	1999-10-18	2004-04-13	Lipocine, Inc.	Emulsion compositions for polyfunctional active ingredients
GB2355454A (en)	1999-10-20	2001-04-25	Ferring Bv	Antidiuretic agents
US6264981B1 (en)	1999-10-27	2001-07-24	Anesta Corporation	Oral transmucosal drug dosage using solid solution
US6558695B2 (en)	1999-12-16	2003-05-06	Dermatrends, Inc.	Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
GB0000079D0 (en)	2000-01-05	2000-02-23	Ferring Bv	Novel antidiuretic agents
EP1296730B2 (en)	2000-01-07	2014-07-30	Valeritas, Inc.	Injection device
US20070032410A1 (en)	2000-01-11	2007-02-08	Atossa Healthcare, Inc.	Compositions and methods for the treatment of psychiatric disorders
AT409081B (de) *	2000-02-16	2002-05-27	Gebro Pharma Gmbh	Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
GB0015601D0 (en)	2000-06-26	2000-08-16	Ferring Bv	Novel antidiuretic agents
US6348486B1 (en)	2000-10-17	2002-02-19	American Home Products Corporation	Methods for modulating bladder function
DE60138407D1 (de)	2000-10-26	2009-05-28	Alza Corp	Transdermales arzneistoffverabreichungssytem mit beschichteten mikrovorsprüngen
EP2578252B1 (en)	2000-11-30	2019-01-09	Valeritas, Inc.	Device with substantially freely movable micro-probe over the housing
CA2430499C (en)	2000-11-30	2012-05-22	Biovalve Technologies, Inc.	Injection systems
US9302903B2 (en)	2000-12-14	2016-04-05	Georgia Tech Research Corporation	Microneedle devices and production thereof
WO2002050584A2 (en)	2000-12-21	2002-06-27	Biovalve Technologies, Inc.	Microneedle array systems
IL157822A0 (en)	2001-03-16	2004-03-28	Alza Corp	Transdermal patch for administering fentanyl
DE60222879T2 (de)	2001-04-12	2008-07-24	Wyeth	Cyclohexylphenyl vasopressin agonisten
ATE355843T1 (de)	2001-04-12	2007-03-15	Wyeth Corp	N-biphenylcarbonyl- und n-phenylpyridylcarbonyl substituierte bi- and tricyclische azepine und diazepine als vasopressin-agonisten
US7022699B2 (en)	2001-04-12	2006-04-04	Wyeth	Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators
US6872405B2 (en) *	2001-05-10	2005-03-29	Yamanouchi Pharmaceutical Co., Ltd.	Quick-disintegrating tablet in buccal cavity and manufacturing method thereof
US6509040B1 (en) *	2001-06-22	2003-01-21	R.P. Scherer Corporation	Fast dispersing dosage forms essentially free of mammalian gelatin
US6667277B2 (en)	2001-08-24	2003-12-23	National Starch And Chemical Investment Holding Corporation	Water dispersible starch based physical form modification of agricultural agents
GB2391480B (en)	2002-08-05	2007-02-28	Caretek Medical Ltd	Drug delivery system
US7615234B2 (en)	2001-09-11	2009-11-10	Glide Pharmaceutical Technologies Limited	Drug delivery technology
AU2002330453B2 (en)	2001-09-13	2008-04-17	Kissei Pharmaceutical Co., Ltd	Crystals of hydroxynorephedrine derivative
BR0212718B1 (pt) *	2001-09-21	2012-01-10		dispositivo de dosagem com um reservatório de meios, bem como, com um dispositivo de bombeamento.
US6723077B2 (en)	2001-09-28	2004-04-20	Hewlett-Packard Development Company, L.P.	Cutaneous administration system
US6893655B2 (en)	2001-10-09	2005-05-17	3M Innovative Properties Co.	Transdermal delivery devices
PL369999A1 (en)	2001-11-16	2005-05-16	Yamanouchi Pharmaceutical Co, Ltd.	4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivatives or salts thereof
DE60307082D1 (de)	2002-05-07	2006-09-07	Ferring Bv	In der mundhöhle dispergierbare phamarzeutische zusammensetzung mit desmopressin
GB0210397D0 (en)	2002-05-07	2002-06-12	Ferring Bv	Pharmaceutical formulations
WO2003097080A1 (en)	2002-05-15	2003-11-27	Sun Pharmaceutical Industries Limited	A stable aqueous composition of a peptide
US6945952B2 (en)	2002-06-25	2005-09-20	Theraject, Inc.	Solid solution perforator for drug delivery and other applications
ITMI20021684A1 (it) *	2002-07-29	2004-01-29	Therapicon Srl	Composizione farmaceutica di peptide nasale
WO2004030743A2 (en)	2002-09-30	2004-04-15	Alza Corporation	Drug delivery device having coated microprojections incorporating vasoconstrictors
BR0314754A (pt)	2002-10-09	2005-07-26	Toray Industries	Agente terapêutico ou profilático para a frequência urinária ou a incontinência urinária ou um seu sal de adição de ácido farmaceuticamente aceitável, método para terapia ou profilaxia para frequência urinária, urgência urinária ou incontinência urinária, uso de um derivado de morfina tendo um grupo heterocìclico contendo nitrogênio ou de um seu sal de adição de ácido farmaceuticamente aceitável, derivado de morfina ou um seu sal de adição de ácido farmaceuticamente aceitável, produto farmacêutico, e, composição farmacêutica
US7383084B2 (en)	2002-10-31	2008-06-03	Transpharma Medical Ltd.	Transdermal delivery system for dried particulate or lyophilized medications
CN100457079C (zh)	2002-11-14	2009-02-04	宇部兴产株式会社	化妆品组合物
DE10259934B3 (de)	2002-12-20	2004-10-14	H.C. Starck Gmbh	Verfahren zur Herstellung von Formteilen aus Niob oder Tantal durch elektrochemisches Ätzen und so erhältliche Formteile
AR042815A1 (es)	2002-12-26	2005-07-06	Alza Corp	Dispositivo de suministro de agente activo que tiene miembros compuestos
US20040155167A1 (en) *	2003-02-07	2004-08-12	Ergodontics	System and method of mounting a display screen via a pendulum type mount
KR100882154B1 (ko)	2003-04-28	2009-02-06	아스텔라스세이야쿠 가부시키가이샤	4,4-디플루오로-1,2,3,4-테트라하이드로-5ｈ-1-벤즈아제핀 유도체 또는 이의 염 및 이를 포함하는 의약 조성물
US20060193825A1 (en)	2003-04-29	2006-08-31	Praecis Phamaceuticals, Inc.	Pharmaceutical formulations for sustained drug delivery
US7094545B2 (en)	2003-04-30	2006-08-22	Ferring Bv	Pharmaceutical composition as solid dosage form and method for manufacturing thereof
PT1473029E (pt)	2003-04-30	2005-05-31	Ferring Bv	Forma de dosagem solida compreendendo desmopressina
ES2290738T3 (es)	2003-06-30	2008-02-16	Alza Corporation	Procedimiento para revestir microproyecciones de perforacion de la piel.
DK1500390T3 (da)	2003-07-25	2005-09-19	Ferring Bv	Farmaceutisk præparat som fast dosisform og fremgangsmåde til fremstilling deraf
CN1826099B (zh)	2003-07-25	2010-06-09	凡林有限公司	固体剂型药物组合物及其制造方法
US6930932B2 (en)	2003-08-27	2005-08-16	Hewlett-Packard Development Company, L.P.	Data signal reception latch control using clock aligned relative to strobe signal
CA2543086A1 (en)	2003-10-24	2005-05-12	Alza Corporation	Pretreatment method and system for enhancing transdermal drug delivery
CA2543084A1 (en)	2003-10-24	2005-05-12	Alza Corporation	Apparatus and method for enhancing transdermal drug delivery
US7097631B2 (en)	2003-10-31	2006-08-29	Alza Corporation	Self-actuating applicator for microprojection array
CA2545194C (en)	2003-11-10	2014-10-21	Seymour H. Fein	Pharmaceutical compositions including low dosages of desmopressin
DK1530967T3 (da)	2003-11-13	2006-07-03	Ferring Bv	Blisterpakning og dertil hörende fast dosisform
US7344725B2 (en)	2003-11-25	2008-03-18	Alcon, Inc.	Use of inorganic nanoparticles to stabilize hydrogen peroxide solutions
DK1550439T3 (da)	2003-12-29	2006-04-03	Ferring Bv	Fremgangsmåde til fremstilling af faste dosisformer af desmopressin
US7018653B2 (en)	2003-12-29	2006-03-28	Ferring B.V.	Method for preparing solid dosage form of desmopressin
CA2490601C (en)	2003-12-29	2006-05-02	Ferring B.V.	Method for preparing solid dosage form of desmopressin
MXPA06007832A (es)	2004-01-09	2007-01-26	Johnson & Johnson	Metodo y sistema de suministro de agente transdermico asistido por frecuencia.
DK1797109T3 (en)	2004-09-09	2016-04-11	Yeda Res & Dev	MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof
US7097776B2 (en)	2004-10-22	2006-08-29	Hewlett-Packard Development Company, L.P.	Method of fabricating microneedles
US20060093658A1 (en)	2004-10-26	2006-05-04	Gayatri Sathyan	Apparatus and method for transdermal delivery of desmopressin
US20080009801A1 (en)	2004-12-02	2008-01-10	Nickel Janice H	Method for dispensing material into a drug delivery device
US7180274B2 (en)	2004-12-10	2007-02-20	Aimtron Technology Corp.	Switching voltage regulator operating without a discontinuous mode
WO2006085101A2 (en)	2005-02-10	2006-08-17	Orexo Ab	Pharmaceutical compositions useful in the transmucosal administration of drugs
CN101218223A (zh)	2005-04-22	2008-07-09	惠氏公司	苯并二烷和苯并二氧戊环衍生物及其应用
BRPI0610027A2 (pt)	2005-04-22	2010-05-18	Wyeth Corp	derivados de cromano e cromeno e usos dos mesmos
US7856263B2 (en)	2005-04-22	2010-12-21	Travanti Pharma Inc.	Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis
EP1871356A1 (en)	2005-04-22	2008-01-02	Wyeth a Corporation of the State of Delaware	Dihydrobenzofuran derivatives and uses thereof
MX2007013021A (es)	2005-04-22	2008-01-11	Wyeth Corp	Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c.
WO2006116150A1 (en)	2005-04-22	2006-11-02	Wyeth	Dihydrobenzofuran derivatives and uses thereof
CN101203217A (zh)	2005-04-24	2008-06-18	惠氏公司	调节膀胱功能的方法
EP1893130A4 (en)	2005-06-17	2015-08-26	Georgia Tech Res Inst	COATED MICROSTRUCTURES AND METHOD FOR THE PRODUCTION THEREOF
US20080195035A1 (en)	2005-06-24	2008-08-14	Frederickson Franklyn L	Collapsible Patch and Method of Application
WO2007083323A2 (en)	2006-01-23	2007-07-26	Panacea Biotec Limited.	Modified release oral dosage form comprising desmopressin
SE528446C2 (sv)	2006-03-02	2006-11-14	Ferring Int Ct Sa	Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
US8101114B2 (en)	2006-05-01	2012-01-24	Georgia Tech Research Corporation	Particle based molding
KR20140143461A (ko)	2007-08-06	2014-12-16	알레간 인코포레이티드	데스모프레신 약물 전달을 위한 방법 및 장치
US20100160214A1 (en) *	2008-12-22	2010-06-24	Serenity Pharmaceuticals Corporation	Desmopressin composition

2002
- 2002-05-07 GB GBGB0210397.6A patent/GB0210397D0/en not_active Ceased
- 2002-09-20 WO PCT/IB2002/004036 patent/WO2003094885A1/en not_active Application Discontinuation
- 2002-09-20 AU AU2002337419A patent/AU2002337419A1/en not_active Abandoned
2003
- 2003-02-26 UY UY27683A patent/UY27683A1/es not_active Application Discontinuation
- 2003-03-20 AR ARP030100988A patent/AR039092A1/es not_active Application Discontinuation
- 2003-05-06 AR ARP030101599A patent/AR039794A1/es not_active Application Discontinuation
- 2003-05-06 WO PCT/US2003/014463 patent/WO2004041153A2/en not_active Application Discontinuation
- 2003-05-06 AU AU2003299480A patent/AU2003299480A1/en not_active Abandoned
- 2003-05-06 MY MYPI20031700A patent/MY131153A/en unknown
- 2003-05-06 TW TW092112320A patent/TWI315202B/zh not_active IP Right Cessation
- 2003-05-07 SI SI200330434T patent/SI1501534T1/sl unknown
- 2003-05-07 CN CNA200610172805XA patent/CN1981745A/zh active Pending
- 2003-05-07 EP EP03727870A patent/EP1501534B1/en not_active Expired - Lifetime
- 2003-05-07 CN CNB038098881A patent/CN1319592C/zh not_active Expired - Lifetime
- 2003-05-07 AT AT03727870T patent/ATE333886T1/de active
- 2003-05-07 UA UA20041109074A patent/UA85664C2/ru unknown
- 2003-05-07 RU RU2004130435/15A patent/RU2292903C2/ru active
- 2003-05-07 US US10/513,437 patent/US7560429B2/en not_active Expired - Lifetime
- 2003-05-07 MX MXPA04010926A patent/MXPA04010926A/es active IP Right Grant
- 2003-05-07 KR KR1020047017821A patent/KR100632455B1/ko active IP Right Grant
- 2003-05-07 UY UY27796A patent/UY27796A1/es not_active Application Discontinuation
- 2003-05-07 ES ES03727870.2T patent/ES2266820T4/es not_active Expired - Lifetime
- 2003-05-07 DK DK03727870.2T patent/DK1501534T5/da active
- 2003-05-07 PL PL375497A patent/PL208482B1/pl unknown
- 2003-11-12 US US10/706,100 patent/US7799761B2/en not_active Expired - Lifetime
2004
- 2004-10-12 IL IL164519A patent/IL164519A/en active IP Right Grant
- 2004-10-22 ZA ZA200408596A patent/ZA200408596B/en unknown
2005
- 2005-07-20 HK HK05106142A patent/HK1074393A1/xx not_active IP Right Cessation
2007
- 2007-05-04 US US11/744,615 patent/US7405203B2/en not_active Expired - Lifetime
2008
- 2008-07-15 US US12/173,072 patent/US8143225B2/en not_active Expired - Fee Related
- 2008-07-15 US US12/173,074 patent/US7579321B2/en not_active Expired - Fee Related
2009
- 2009-06-18 US US12/487,116 patent/US7947654B2/en not_active Expired - Lifetime
- 2009-11-06 US US12/613,855 patent/US20100056436A1/en not_active Abandoned
2011
- 2011-05-18 US US13/110,619 patent/US8802624B2/en not_active Expired - Lifetime
2012
- 2012-08-30 US US13/599,768 patent/US20120322734A1/en not_active Abandoned
2014
- 2014-07-09 US US14/326,939 patent/US9220747B2/en not_active Expired - Lifetime
2015
- 2015-11-20 US US14/947,261 patent/US9504647B2/en not_active Expired - Fee Related
2016
- 2016-02-16 AR ARP160100416A patent/AR107948A2/es not_active Application Discontinuation
- 2016-10-25 US US15/333,503 patent/US9919025B2/en not_active Expired - Lifetime
2018
- 2018-01-26 US US15/881,123 patent/US10307459B2/en not_active Expired - Lifetime
2020
- 2020-07-09 US US16/924,843 patent/US20210161810A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20170112895A1 (en)	2017-04-27
GB0210397D0 (en)	2002-06-12
MXPA04010926A (es)	2005-02-14
AR107948A2 (es)	2018-07-04
AR039092A1 (es)	2005-02-09
DK1501534T5 (da)	2014-12-15
IL164519A0 (en)	2005-12-18
US7560429B2 (en)	2009-07-14
CN1981745A (zh)	2007-06-20
DK1501534T3 (da)	2006-11-20
TWI315202B (en)	2009-10-01
WO2003094885A1 (en)	2003-11-20
US9504647B2 (en)	2016-11-29
CN1319592C (zh)	2007-06-06
AU2003299480A1 (en)	2004-06-07
EP1501534B1 (en)	2006-07-26
AR039794A1 (es)	2005-03-02
RU2292903C2 (ru)	2007-02-10
KR20050009999A (ko)	2005-01-26
IL164519A (en)	2009-09-22
US20180280469A1 (en)	2018-10-04
US9919025B2 (en)	2018-03-20
US20090005432A1 (en)	2009-01-01
US7947654B2 (en)	2011-05-24
US8802624B2 (en)	2014-08-12
US20120071538A1 (en)	2012-03-22
US20210161810A1 (en)	2021-06-03
US20050232997A1 (en)	2005-10-20
MY131153A (en)	2007-07-31
US9220747B2 (en)	2015-12-29
US20150150938A1 (en)	2015-06-04
RU2004130435A (ru)	2005-08-10
AU2002337419A1 (en)	2003-11-11
UY27796A1 (es)	2003-11-28
WO2004041153A2 (en)	2004-05-21
TW200400054A (en)	2004-01-01
KR100632455B1 (ko)	2006-10-11
EP1501534A2 (en)	2005-02-02
US7405203B2 (en)	2008-07-29
US20090318665A1 (en)	2009-12-24
US20040138098A1 (en)	2004-07-15
US7799761B2 (en)	2010-09-21
ATE333886T1 (de)	2006-08-15
ES2266820T4 (es)	2014-12-30
AU2003299480A8 (en)	2004-06-07
UA85664C2 (ru)	2009-02-25
WO2004041153A3 (en)	2004-08-26
US20160175246A1 (en)	2016-06-23
HK1074393A1 (en)	2005-11-11
US7579321B2 (en)	2009-08-25
US8143225B2 (en)	2012-03-27
CN1649615A (zh)	2005-08-03
UY27683A1 (es)	2003-12-31
US10307459B2 (en)	2019-06-04
US20070265207A1 (en)	2007-11-15
PL375497A1 (en)	2005-11-28
US20120322734A1 (en)	2012-12-20
ES2266820T3 (es)	2007-03-01
US20080274951A1 (en)	2008-11-06
PL208482B1 (pl)	2011-05-31
US20100056436A1 (en)	2010-03-04
SI1501534T1 (sl)	2006-12-31

Publication	Publication Date	Title
ZA200408596B (en)	2006-06-28	Demsmopressin in an orodispersible dosage form
AU2003233118B8 (en)	2009-07-30	Desmopressin in an orodispersible dosage form
CA2545194C (en)	2014-10-21	Pharmaceutical compositions including low dosages of desmopressin
KR100613550B1 (ko)	2006-08-16	이바브라딘을 포함하는 구강내분산성 약제 조성물